Mannkind (MNKD) Cash from Financing Activities (2010 - 2026)
Mannkind (MNKD) reported Cash from Financing Activities of -$35.4 million for Q1 2026, down 2647.19% year-over-year from $1.4 million in Q1 2025, and down 114.31% quarter-over-quarter from $247.4 million in Q4 2025.
Mannkind (MNKD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash from Financing Activities data on file, last reported at -$35.4 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$35.4 million, down 2647.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $278.3 million (up 310.2% YoY), and the FY2025 annual result was $315.1 million, up 329.55% from the prior year.
- Cash from Financing Activities fell to -$35.4 million in Q1 2026 per MNKD's latest filing, from $247.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $247.4 million in Q4 2025 and troughed at -$86.9 million in Q4 2024.
- A 5-year average of $17.7 million and a median of -$283000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 4915.26% in 2023, then plunged 2647.19% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $2.8 million in 2022, then jumped by 4915.26% to $141.7 million in 2023, then plunged by 161.33% to -$86.9 million in 2024, then soared by 384.71% to $247.4 million in 2025, then plunged by 114.31% to -$35.4 million in 2026.
- Business Quant data shows MNKD's Cash from Financing Activities at -$35.4 million in Q1 2026, $247.4 million in Q4 2025, and $71.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | -35.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.41 Mn |
| Mar 31, 2026 | -35.41 Mn |
| Dec 31, 2025 | 247.41 Mn |
| Dec 31, 2025 | 247.41 Mn |
| Sep 30, 2025 | 71.81 Mn |
| Sep 30, 2025 | 71.81 Mn |
| Jun 30, 2025 | -5.51 Mn |
| Jun 30, 2025 | -5.51 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | -86.90 Mn |
| Dec 31, 2024 | -86.90 Mn |
| Sep 30, 2024 | -2.34 Mn |
| Sep 30, 2024 | -2.34 Mn |
| Jun 30, 2024 | -44.55 Mn |
| Jun 30, 2024 | -44.55 Mn |
| Mar 31, 2024 | -3.47 Mn |
| Mar 31, 2024 | -3.47 Mn |
| Dec 31, 2023 | 141.68 Mn |
| Dec 31, 2023 | 141.68 Mn |